Glycated Albumin's Clinical Effectiveness in The Diabetes Diagnosis: Glycated Albumin's Clinical Effectiveness in Diabetes

Summeira  Jabeen Shah; Hajira  Ishaq; Hina  Hakeem; Saima  Shaheen; Sikandar  Ali Khan; Sosan  Rauf; Hina  Mir; Sudhair  Abbas Bangash; Muhammad  Ali; Irfan  Ullah

doi:10.54393/pbmj.v5i5.449

Authors

Summeira Jabeen Shah Department of Biochemistry, Pak International Medical College, Peshawar
Hajira Ishaq Department of Biochemistry, Khyber Medical College, Peshawar
Hina Hakeem Department of Biochemistry, Peshawar Medical College, Peshawar
Saima Shaheen Department of Biochemistry, Khyber Girls Medical College, Peshawar
Sikandar Ali Khan Department of Biochemistry, Khyber Girls Medical College, Peshawar
Sosan Rauf Department of Biochemistry, Khyber Girls Medical College, Peshawar
Hina Mir Department of Biochemistry, Shaheed Benazir Bhutto Women University, Peshawar, Pakistan
Sudhair Abbas Bangash Faculty of Life Science, Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Pakistan
Muhammad Ali Department of Life Sciences, School of Science, University of Management and Technology (UMT), Lahore, Pakistan
Irfan Ullah Department of Life Sciences, School of Science, University of Management and Technology (UMT), Lahore, Pakistan

DOI:

https://doi.org/10.54393/pbmj.v5i5.449

Keywords:

Hba1c, Glycated Albumin, Effectiveness, Diabetes, Diagnosis

Abstract

In places like Asia, the use of Glycated Albumin (GA) as a diabetes diagnostic marker has increased in recent years. Glucophage (GA) has been shown to be effective in the diagnosis of diabetes in asymptomatic people who have medical records and rising blood glucose levels that indicate a high risk of acquiring diabetes. Objective: To find out the impact of glycated albumin in the diagnosis of diabetes mellitus. Methods: This study included a total of 250 participants including one or even more diabetes risk factors or Fasting Plasma Glucose (FPG) varying from 5.6 molar ratio to 6.9 molar ratio but no symptoms of diabetes. The lab Taurus device was used to assess plasma GA using an enzymatic technique. Results: Among the patients, 20(6.9%) had HbA1c greater than 49 molar ratio. As per the outcomes, GA's diagnosed diabetic participants with a sensitivity of 73.6% (95% confidence interval: 44.4 – 92.4) and a specificity of 74.5% (95 % confidence interval: 44.4 – 92.4) at a cut-off of 15% (Area under the ROC curve: 0.79; 96%, CI: 0.79-0.99; P≤ 0.01), which corresponds to the better diagnostic performance. At different cut-offs for diabetes diagnosis, the specificity and sensitivity of GA are examined. The 14.2% cut-offs were linked with greater sensitivity (89.5%; 96%, CI: 59.2 – 89.5) and adequate specificity (63.6%; 95%, CI: 52.9 – 66.5), making it more appropriate for screening at-risk individuals. Conclusions: This research proves the clinical efficacy of GA for diabetes diagnosis participants at risk for the disease. Further investigation is required to evaluate the relative relevance of GA in relation to the other diabetes screening indicators

References

Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014 Jun 10;433:96-104. doi: 10.1016/j.cca.2014.03.001.

Muthanna F, Karuppannan M, Abdulrahman E, Uitrakul S, Rasool BA, Mohammed AH. Prevalence and Associated Factors of Anemia among Breast Cancer Patients Undergoing Chemotherapy: A Prospective Study. Advances in Pharmacological and Pharmaceutical Sciences. 2022 Apr 14;2022. doi.org/10.1155/2022/7611733.

Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010;57(9):751-62. doi: 10.1507/endocrj.k10e-138.

Arif S, Zia T, Qayyum Z, Mustafa G, Ateeq M, Farhad S et al. Prevalence and Risk Factors of Covid-19 Mortality and its Impact on Social Life of Pakistani Population. Pakistan Journal of Medical & Health Sciences. 2022 Apr 27;16(03):800-.doi.org/10.53350/pjmhs22163800.

Furusyo N, Hayashi J. Glycated albumin and diabetes mellitus. Biochim Biophys Acta. 2013 Dec;1830(12):5509-14. doi: 10.1016/j.bbagen.2013.05.010.

Dozio E, Di Gaetano N, Findeisen P, Corsi Romanelli MM. Glycated albumin: from biochemistry and laboratory medicine to clinical practice. Endocrine. 2017 Mar;55(3):682-690. doi: 10.1007/s12020-016-1091-6.

Arif S, Zia T, Mustafa G, Qayyum Z, Ateeq M, Faiz MJ et al. Knowledge, Attitude and Practices of Medical Students Regarding Covid-19, Pakistan. Pakistan Journal of Medical & Health Sciences. 2022 Apr 27;16(03):783-. doi.org/10.53350/pjmhs22163783.

Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol. 2015 Mar;9(2):169-76. doi: 10.1177/1932296814567227.

Wu WC, Ma WY, Wei JN, Yu TY, Lin MS, Shih SR et al. Serum Glycated Albumin to Guide the Diagnosis of Diabetes Mellitus. PLoS One. 2016 Jan 14;11(1):e0146780. doi: 10.1371/journal.pone.0146780.

Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia. 2011 Dec;54(12):3028-36. doi: 10.1007/s00125-011-2310-6.

Freitas PAC, Ehlert LR, Camargo JL. Glycated albumin: a potential biomarker in diabetes. Arch Endocrinol Metab. 2017 May-Jun;61(3):296-304. doi: 10.1590/2359-3997000000272.

Ghosh S, Datta D, Cheema M, Dutta M, Stroscio MA. Aptasensor based optical detection of glycated albumin for diabetes mellitus diagnosis. Nanotechnology. 2017 Oct 27;28(43):435505. doi: 10.1088/1361-6528/aa893a.

Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab. 2013 Dec 7;3(2):94-108. doi: 10.1016/j.molmet.2013.11.006.

Roohk HV, Zaidi AR. A review of glycated albumin as an intermediate glycation index for controlling diabetes. J Diabetes Sci Technol. 2008 Nov;2(6):1114-21. doi: 10.1177/193229680800200620.

Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care. 2010 Feb;33(2):270-2. doi: 10.2337/dc09-1002.

Muthanna FM, Hassan BA, Karuppannan M, Mohammed AH. Evaluation of the impact of anaemia on quality of life among breast cancer patients undergoing chemotherapy in Malaysia. Journal of Pharmaceutical Health Services Research. 2021 Jun;12(2):310-2. doi.org/10.1093/jphsr/rmaa033.

Araki T, Ishikawa Y, Okazaki H, Tani Y, Toyooka S, Satake M et al. Introduction of glycated albumin measurement for all blood donors and the prevalence of a high glycated albumin level in Japan. J Diabetes Investig. 2012 Dec 20;3(6):492-7. doi: 10.1111/j.2040-1124.2012.00224.x.

Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010 Apr;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337.

Maesa JM, Fernández-Riejos P, Mora CS, de Toro M, Valladares PM, González-Rodriguez C. Evaluation of Bio-Rad D-100 HbA1c analyzer against Tosoh G8 and Menarini HA-8180V. Pract Lab Med. 2016 May 14;5:57-64. doi: 10.1016/j.plabm.2016.05.002.

Shimizu I, Kohzuma T, Koga M. A proposed glycemic control marker for the future: glycated albumin. J Lab Precis Med. 2019;4:23. doi.org/10.21037/jlpm.2019.05.01.

Kohzuma T, Tao X, Koga M. Glycated albumin as biomarker: Evidence and its outcomes. J Diabetes Complications. 2021 Nov;35(11):108040. doi: 10.1016/j.jdiacomp.2021.108040.

Muthanna FMS, Karuppannan M, Hassan BAR, Mohammed AH. Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy. Osong Public Health Res Perspect. 2021 Apr;12(2):115-125. doi: 10.24171/j.phrp.2021.12.2.09.

Welsh KJ, Kirkman MS, Sacks DB. Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions. Diabetes Care. 2016 Aug;39(8):1299-306. doi: 10.2337/dc15-2727.

Mo Y, Ma X, Li H, Ran X, Yang W, Li Q et al. Relationship between glycated albumin and glycated hemoglobin according to glucose tolerance status: A multicenter study. Diabetes Res Clin Pract. 2016 May;115:17-23. doi: 10.1016/j.diabres.2016.03.003.

Testa R, Ceriotti F, Guerra E, Bonfigli AR, Boemi M, Cucchi M et al. Glycated albumin: correlation to HbA1c and preliminary reference interval evaluation. Clin Chem Lab Med. 2017 Feb 1;55(2):e31-e33. doi: 10.1515/cclm-2016-0512.

Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ura K, Hiramine S, Mitsumoto F et al. Glycated albumin as a diagnostic tool for diabetes in a general Japanese population. Metabolism. 2015 Jun;64(6):698-705. doi: 10.1016/j.metabol.2015.03.003.

Takei I, Hoshino T, Tominaga M, Ishibashi M, Kuwa K, Umemoto M et al. Committee on Diabetes Mellitus Indices of the Japan Society of Clinical Chemistry-recommended reference measurement procedure and reference materials for glycated albumin determination. Ann Clin Biochem. 2016 Jan;53(Pt 1):124-32. doi: 10.1177/0004563215599178.

Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J. Performance of A1C for the classification and prediction of diabetes. Diabetes Care. 2011 Jan;34(1):84-9. doi: 10.2337/dc10-1235.

Huang Y, Hu Y, Ma YU, Ye G. Glycated albumin is an optimal biomarker for gestational diabetes mellitus. Exp Ther Med. 2015 Dec;10(6):2145-2149. doi: 10.3892/etm.2015.2808.

Gul A, Sharif N, Ahmed S. Diabetes: comparison of HbA1c and serum glycated albumin levels as monitoring tool. The Professional Medical Journal. 2018 Jan 10;25(01):109-14. doi: 10.29309/TPMJ/18.4263.